Transforming patient engagement in clinical trials: Moving from a transactional relationship to human-centered care [0.03%]
从交易关系到以人为中心的护理：临床试验中的患者参与转型
Alicia Staley
Alicia Staley
Engagement with patients during the clinical trial process encompasses all of the interactions that those running clinical trials have with the participants. The essence of patient engagement is to ensure patients feel supported, connected ...
Targeting caseinolytic protease P and its AAA1 chaperone for tuberculosis treatment [0.03%]
针对结核病治疗的乳酸蛋白酶P及其AAA1分子伴侣的新药发现
Xin Xu,Laiying Zhang,Tao Yang et al.
Xin Xu et al.
Caseinolytic protease P with its AAA1 chaperone, known as Mycobacterium tuberculosis (Mtb)ClpP1P2 proteolytic machinery, maintains protein homeostasis in Mtb cells and is essential for bacterial survival. It is regarded as an important biol...
Xue Wang,Courtney Bishop,James O&#x;Callaghan et al.
Xue Wang et al.
Neurodegenerative mechanisms affect the brain through a variety of processes that are reflected as changes in brain structure and physiology. Although some biomarkers for these changes are well established, others are at different stages of...
The FDA modernisation act 2.0: Bringing non-animal technologies to the regulatory table [0.03%]
《FDA现代化法案2.0》：将非动物技术引入监管框架
Alastair Stewart,Delphine Denoyer,Xumei Gao et al.
Alastair Stewart et al.
The FDA modernisation Act 2.0 marks a game-changing legislation enabling drug registration without the absolute requirement for the use of animals in safety toxicology assessment. We discuss landmark developments in the legislation under wh...
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities [0.03%]
核酸治疗的口服给药：挑战、策略和机遇
Xiaohe Jiang,Ning Wang,Chang Liu et al.
Xiaohe Jiang et al.
In recent decades, advances in chemical synthesis and delivery systems have accelerated the development of therapeutic nucleic acids, several of which have been approved by the Us Food and Drug Administration (FDA). Oral nucleic acid delive...
Fahad Hussain Mohammed,Franz Cemic,Jürgen Hemberger et al.
Fahad Hussain Mohammed et al.
Epigenetics targets are the newest branches for building a novel platform of drugs for preventive and regenerative skin health care. Epigenetic regions [vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), tra...
How can we unleash the potential of external controls in clinical trials? [0.03%]
我们如何在临床试验中发挥外部控制的潜力？
Philipp Schwarz,Ekkehard Brockstedt
Philipp Schwarz
Prasad V Bharatam,Omkar R Valanju,Aabid A Wani et al.
Prasad V Bharatam et al.
Tautomerism is an important phenomenon exhibited by many drugs. As we discuss in this review, identifying the different tautomers of drugs and exploring their importance in the mechanisms of drug action are integral components of current dr...
Antibacterial nanophotosensitizers in photodynamic therapy: An update [0.03%]
光动力疗法中的 antibacterial 纳米光敏剂：最新进展
Zahi Badran,Betul Rahman,Paul De Bonfils et al.
Zahi Badran et al.
Bacterial infections constitute a major challenge of clinical medicine, particularly in specialties such as dermatology and dental medicine. Antiseptics and antibiotics are the main adjunctive therapies to anti-infective procedures in these...
Artificial intelligence as a smart approach to develop antimicrobial drug molecules: A paradigm to combat drug-resistant infections [0.03%]
开发抗菌药物分子的智能方法：对抗耐药感染的范例
Absar Talat,Asad U Khan
Absar Talat
Antimicrobial resistance (AMR) is a silent pandemic with the third highest global mortality. The antibiotic development pipeline is scarce even though AMR has escalated uncontrollably. Artificial intelligence (AI) is a revolutionary approac...